ETFdb Logo
  • ETF Database
  • Channels
    • Themes
      • Active ETF
      • Alternatives Channel
      • Artificial Intelligence
      • China Insights
      • Climate Insights
      • Core Strategies
      • Crypto
      • Disruptive Technology
      • Energy Infrastructure
      • ETF Building Blocks
      • ETF Education
      • ETF Investing
      • ETF Strategist
      • Faith-Based Investing
      • Financial Literacy
      • Fixed Income
      • Free Cash Flow
      • Innovative ETFs
      • Invest Beyond Cash
      • Leveraged & Inverse
      • Modern Alpha
      • Portfolio Strategies
      • Tax Efficient Income
    • Asset Class
      • Equity
        • U.S. Equity
        • Int'l Developed
        • Emerging Market Equities
      • Alternatives
        • Gold/Silver/Critical Materials
        • Crypytocurrency
        • Currency
        • Volatility
      • Fixed Income
        • Investment Grade Corporates
        • US Treasuries & TIPS
        • High Yield Corporates
        • Int'l Fixed Income
    • ETF Ecosystem
    • ETFs in Canada
    • Market Outlook
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Database Categories
    • Indexes
    • Scenario Analysis
    • Watchlists
    • Head-To-Head ETF Comparison Tool
    • Mutual Fund To ETF Converter
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • Gaining Perspective Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. ETF Education Channel
  2. QQQJ Has Inroads to Rebound in Biotech
ETF Education Channel
Share

QQQJ Has Inroads to Rebound in Biotech

Tom LydonJun 17, 2022
2022-06-17

Biotechnology stocks and exchange traded funds are in the midst of one of their longest declines in recent memory, providing investors with ample reasons to avoid these assets.

On the other hand, some analysts are becoming more constructive on biotech stocks. That’s a positive, and every rebound has to start somewhere, but investors have no way of knowing exactly when a biotech resurgence could materialize in earnest.

One way of contending with that situation is to consider ETFs that have decent biotech exposure, but aren’t solely focused on that industry. In that group, the Invesco NASDAQ Next Gen 100 ETF (QQQJ B) is an idea to evaluate.

QQQJ, which tracks the NASDAQ Next Generation 100 Index, allocates nearly 20% of its weight to healthcare stocks, its second-largest sector exposure behind technology. The bulk of QQQJ’s 20 healthcare holdings are biotech names, indicating that QQQJ offers investors a solid avenue for accessing potential value in the battered biotech space.

“A third of that universe is trading below cash on balance sheet, so you’re looking at companies in negative enterprise value position. That seems like a very attractive entry point, if you buy into the long-term growth story,” said Luke Barrs, head of fundamental equity, EMEA at Goldman Sachs Asset Management, in an interview with CNBC.

Another reason QQQJ could be a credible idea for long-term investors wagering on a biotech rebound is the point that it’s not a large-cap-heavy fund. The average market capitalization of QQQJ’s 100 components is $19.64 billion, according to Invesco data.

Specific to biotech, QQQJ’s average market capitalization is relevant because it implies that the ETF could benefit when industry consolidation resumes because some of its holdings could be credible takeover targets. In fact, some have already received speculation to that effect.

“If you think about the exit strategy for some of these businesses, clearly the opportunity for M&A in this space — where large pharma companies could step in and acquire some of these unique and new technologies — is very attractive,” Goldman’s Barrs told CNBC.

BioMarin Pharmaceutical (NASDAQ:BMRN) is among the mid-cap biotech stocks that some analysts recently highlighted as value ideas, and that’s one of QQQJ’s healthcare holdings. Horizon Therapeutics (NASDAQ:HZNP) and Incyte Corp (NASDAQ:INCY) — two other QQQJ member firms — are among the mid-cap biotech names that have recently been mentioned as potential takeover targets.

For more news, information, and strategy, visit the ETF Education Channel.

Loading Articles...
Our Sites
  • VettaFi
  • Advisor Perspectives
  • ETF Trends
Tools
  • ETF Screener
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Database Pro
More Tools
  • Financial Advisor & RIA Center
Explore ETFs
  • ETF News
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Information
  • Contact Us
  • Terms of Use and Privacy Policy
  • © 2025 VettaFi LLC. All rights reserved.

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X